For effective use in detecting specific types of cancer, tumor-targeting nanoparticles must evade the immune system, remain intact for a clinically relevant time frame, and show specificity for the targeted tumor type. At last week’s San Antonio Breast Cancer Symposium, Imagion Biosystems’ Biochemistry Research Associate Carrie Weldon presented a poster describing recent collaborative work with researchers at the University of New Mexico and Sandia National Laboratories using Her2 Breast Cancer nanoparticles. Data presented indicate that PEG (polyethylene glycol) -coated nanoparticles last longer in blood circulation than uncoated particles while targeting Her2+ tumor tissues in mice. Download the poster “Specific detection of anti-Her2 PEGylated PrecisionMRX™ nanoparticles measured using superparamagnetic relaxometry.” (1.1 MB pdf)